2024
Safety of naltrexone in patients with cirrhosis
Thompson R, Taddei T, Kaplan D, Rabiee A. Safety of naltrexone in patients with cirrhosis. JHEP Reports 2024, 6: 101095. PMID: 38961852, PMCID: PMC11220533, DOI: 10.1016/j.jhepr.2024.101095.Peer-Reviewed Original ResearchDrug-induced liver injuryRoussel Uclaf Causality Assessment MethodAlcohol use disorderInitiation of naltrexoneSafety of naltrexoneUse disorderRetrospective studyDevelopment of drug-induced liver injuryRoussel Uclaf Causality Assessment Method scoreLiver injuryLiver diseaseRetrospective study of patientsTreatment of alcohol use disordersTreat alcohol use disorderLiver enzyme elevationAlcohol-related cirrhosisCohort of patientsAlkaline phosphatase elevationDiagnosis of cirrhosisStudy of patientsAssociated with developmentCausality Assessment MethodPrescribed naltrexoneDecompensated cirrhosisEnzyme elevation
2022
COVID-19 and the liver: a narrative review of the present state of knowledge
Thandassery RB, Dranoff JA, Perisetti A, Taddei T. COVID-19 and the liver: a narrative review of the present state of knowledge. Translational Gastroenterology And Hepatology 2022, 0: 0-0. PMID: 36300154, PMCID: PMC9468988, DOI: 10.21037/tgh-20-243.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsChronic liver diseaseLiver diseaseLiver injuryComorbid conditionsAcute respiratory distress syndromeDirect viral cytotoxicityNon-immunosuppressed patientsAdvanced liver diseaseLiver function testsThird of patientsEpithelial cellsRespiratory distress syndromeResolution of diseaseResolution of illnessOngoing pandemicNovel corona virus diseaseType 2 pneumocytesCOVID-19Biliary epithelial cellsGastrointestinal epithelial cellsCorona Virus DiseaseLiver dysfunctionDistress syndromeFunction testsUninterrupted care
2021
Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis
John BV, Schwartz K, Levy C, Dahman B, Deng Y, Martin P, Taddei TH, Kaplan DE. Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis. Hepatology Communications 2021, 5: 1426-1436. PMID: 34430786, PMCID: PMC8369937, DOI: 10.1002/hep4.1720.Peer-Reviewed Original ResearchPrimary biliary cholangitisLiver-related mortalityHepatic decompensationOCA useOCA usersPBC cirrhosisObeticholic acidPropensity score modelBiliary cholangitisScore modelRetrospective cohort studySerious liver injuryTreatment of patientsEffect of treatmentCohort studyPartial respondersLiver injuryMultivariable analysisPotential confoundersC-statisticUS veteransUrsodeoxycholic acidBaseline riskCirrhosisDecompensationProtease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation
Torgersen J, Newcomb CW, Carbonari DM, Rentsch CT, Park LS, Mezochow A, Mehta RL, Buchwalder L, Tate JP, Bräu N, Bhattacharya D, Lim JK, Taddei TH, Justice AC, Lo Re V. Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. Journal Of Hepatology 2021, 75: 1312-1322. PMID: 34333102, PMCID: PMC8604762, DOI: 10.1016/j.jhep.2021.07.021.Peer-Reviewed Original ResearchConceptsSevere hepatic dysfunctionBaseline FIB-4Acute liver injuryHepatic dysfunctionInhibitor-based treatmentHepatic decompensationFIB-4Liver injuryHigh riskDAA therapyHazard ratioAdvanced liver fibrosis/cirrhosisRisk of ALIProtease inhibitor-based regimensProtease inhibitor-based treatmentLiver fibrosis/cirrhosisInhibitor-based regimensHepatitis C infectionSevere liver dysfunctionFibrosis/cirrhosisInhibitor-based therapyAminotransferase elevationChronic HCVALT elevationC infection
2019
Analysis of weekend effect in severe acute liver injury: A nationwide database study
Do A, Ilagan‐Ying Y, Taddei TH. Analysis of weekend effect in severe acute liver injury: A nationwide database study. Health Science Reports 2019, 3: e139. PMID: 32166187, PMCID: PMC7060892, DOI: 10.1002/hsr2.139.Peer-Reviewed Original ResearchSevere acute liver injuryAcute liver injuryHospital mortalityWeekend admissionFull model approachLiver injuryTimely managementLarge national inpatient databaseNational inpatient databaseNationwide database studyHospital-level characteristicsRevision diagnosis codesMultiple logistic regressionSignificant mortality differenceLarger hospital sizeComplete covariate dataHospital-level dataEligible hospitalizationsAdmission dayPayer databasePrimary outcomeHispanic raceMale sexPoor outcomeInpatient Database
2012
HCC Is promoted by bacterial translocation and TLR‐4 signaling: A new paradigm for chemoprevention and management
Toffanin S, Cornella H, Harrington A, Llovet J, Groszmann R, Iwakiri Y, Taddei T. HCC Is promoted by bacterial translocation and TLR‐4 signaling: A new paradigm for chemoprevention and management. Hepatology 2012, 56: 1998-2000. PMID: 23115011, DOI: 10.1002/hep.26080.Peer-Reviewed Original ResearchHepatocellular carcinomaToll-like receptorsIntestinal microbiotaLiver diseaseTranslocation of intestinal bacteriaResident liver cellsAdvanced liver diseaseChronically injured liverHepatocellular carcinoma preventionConsequence of chronic liver injuryTLR-4 signalingChronic liver diseaseChronic liver injuryHepatocellular carcinoma initiationHCC promotionPrevention of apoptosisBacterial translocationTLR-4Liver injuryHepatic inflammationTLR4 activationIncreased proliferationLong-term consequencesTherapeutic targetTLR4